McKesson has issued a voluntary recall for 192 vials of Inflectra (infliximab-dyyb) for injection, 100mg per 10 mL single-dose vial. The recall was initiated because the medication was accidentally distributed when it was supposed to remain in quarantine. This error represents a deviation from Current Good Manufacturing Practice (cGMP) standards.
Products that bypass quarantine and standard quality controls may not meet all safety and potency specifications. There is a risk that the medication may be ineffective or cause unexpected side effects for patients receiving the injection.
Recall #: D-0213-2025; Manufactured by Celltrion, Inc. and distributed by Pfizer Labs.
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.